Glenmark Pharmaceuticals is currently trading at Rs. 782.00, down by 10.05 points or 1.27% from its previous closing of Rs. 792.05 on the BSE.
The scrip opened at Rs. 793.00 and has touched a high and low of Rs. 802.00 and Rs. 759.30 respectively. So far 138044 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 671.50 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs. 809.25 and Rs. 759.30 respectively. The current market cap of the company is Rs. 22128.25 crore.
The promoters holding in the company stood at 46.48% while Institutions and Non-Institutions held 41.92% and 11.60% respectively.
Glenmark Pharmaceuticals has received three observations from the US Food and Drug Administration (USFDA) for its Pithampur, Indore plant, which was inspected by USFDA in February 2016. However, the company has responded to the observations in March 2016. Subsequently, the company received two product approvals from this plant and the company has no outstanding items with the USFDA regarding this plant.
Glenmark is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity), with seven molecules in various stages of clinical development & pre-clinical development. The company has a significant presence in branded generics markets across emerging economies including India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: